OBJECTIVE OF THE STUDY: Recent publications have reported an association between colon cancer and human papillomaviruses (HPV), suggesting that HPV infection of the colonic mucosa may contribute to the development of colorectal cancer. METHODS: The GP5+/GP6+ PCR reverse line blot method was used for detection of 37 types of human papillomavirus (HPV) in DNA from paraffin-embedded or frozen tissues from patients with colorectal cancer (n = 279) and normal adjacent tissue (n = 30) in three different study populations, including samples from the United States (n = 73), Israel (n = 106) and Spain (n = 100). Additionally, SPF10 PCR was run on all samples (n = 279) and the Innogenetics INNO-LiPA assay was performed on a subset of samples (n = 15). RESULTS: All samples were negative for all types of HPV using both the GP5+/GP6+ PCR reverse line blot method and the SPF10 INNO-LiPA method. CONCLUSIONS: We conclude that HPV types associated with malignant transformation do not meaningfully contribute to adenocarcinoma of the colon.
OBJECTIVE OF THE STUDY: Recent publications have reported an association between colon cancer and human papillomaviruses (HPV), suggesting that HPV infection of the colonic mucosa may contribute to the development of colorectal cancer. METHODS: The GP5+/GP6+ PCR reverse line blot method was used for detection of 37 types of human papillomavirus (HPV) in DNA from paraffin-embedded or frozen tissues from patients with colorectal cancer (n = 279) and normal adjacent tissue (n = 30) in three different study populations, including samples from the United States (n = 73), Israel (n = 106) and Spain (n = 100). Additionally, SPF10 PCR was run on all samples (n = 279) and the Innogenetics INNO-LiPA assay was performed on a subset of samples (n = 15). RESULTS: All samples were negative for all types of HPV using both the GP5+/GP6+ PCR reverse line blot method and the SPF10 INNO-LiPA method. CONCLUSIONS: We conclude that HPV types associated with malignant transformation do not meaningfully contribute to adenocarcinoma of the colon.
Authors: Adriaan J C van den Brule; René Pol; Nathalie Fransen-Daalmeijer; Leo M Schouls; Chris J L M Meijer; Peter J F Snijders Journal: J Clin Microbiol Date: 2002-03 Impact factor: 5.948
Authors: Sohrab Bodaghi; Koji Yamanegi; Shu-Yuan Xiao; Maria Da Costa; Joel M Palefsky; Zhi-Ming Zheng Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: Janet R Daling; Margaret M Madeleine; Stephen M Schwartz; Katherine A Shera; Joseph J Carter; Barbara McKnight; Peggy L Porter; Denise A Galloway; James K McDougall; Hisham Tamimi Journal: Gynecol Oncol Date: 2002-02 Impact factor: 5.482
Authors: Elin Ringström; Edward Peters; Masayuki Hasegawa; Marshall Posner; Mei Liu; Karl T Kelsey Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: B Kleter; L J van Doorn; L Schrauwen; A Molijn; S Sastrowijoto; J ter Schegget; J Lindeman; B ter Harmsel; M Burger; W Quint Journal: J Clin Microbiol Date: 1999-08 Impact factor: 5.948
Authors: Justine M Ritchie; Elaine M Smith; Kurt F Summersgill; Henry T Hoffman; Donghong Wang; Jens P Klussmann; Lubomir P Turek; Thomas H Haugen Journal: Int J Cancer Date: 2003-04-10 Impact factor: 7.396
Authors: T Bjørge; A Engeland; T Luostarinen; J Mork; R E Gislefoss; E Jellum; P Koskela; M Lehtinen; E Pukkala; S Ø Thoresen; J Dillner Journal: Br J Cancer Date: 2002-07-01 Impact factor: 7.640
Authors: Andrea N Burnett-Hartman; Polly A Newcomb; Margaret T Mandelson; Denise A Galloway; Margaret M Madeleine; Michelle A Wurscher; Joseph J Carter; Karen W Makar; John D Potter; Stephen M Schwartz Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-08-04 Impact factor: 4.254